

2014 (107)

Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis. *Journal of Hematology and Oncology*. 2014 Mar; 7 21

Alberti C. Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer. *British Journal of Radiology*. 2014 Jan; 88 20140630

Alfaro JA, Sinha A, Kislinger T, Boutros PC. Onco-proteogenomics: Cancer Proteomics Joins Forces with Genomics. *Nature Methods*. 2014 Nov; 11 (11) 1107-1113

Allen HF, Daze KD, Shimbo T, Lai A, Musselman CA, Sims JK, Wade PA, Hof F, Kutateladze TG. Inhibition of histone binding by supramolecular hosts. *Biochemical Journal*. 2014 May; 459 505-512

Al-Mahrouki AA, Iradji S, Tran WT, Czarnota GJ. Cellular characterization of ultrasound-stimulated microbubble radiation enhancement in a prostate cancer xenograft model. *Disease Models and Mechanisms*. 2014 Mar; 7 (3) 363-372

Al-Nedawi Khalid. The yin-yang of microvesicles (exosomes) in cancer biology. *Frontiers in Oncology*. 2014; 4 172

Ban FQ, Leblanc E, Li HF, Munuganti RSN, Frewin K, Rennie PS, Cherkasov A. Discovery of 1H-Indole-2-carboxamides as Novel Inhibitors of the Androgen Receptor Binding Function 3 (BF3). *Journal of Medicinal Chemistry*. 2014 Aug; 57 (15) 6867-6872

Beauregard JM, Pouliot F. New developments in the imaging of metastatic prostate cancer. *Current Opinion in Supportive and Palliative Care*. 2014 Sep; 8 (3) 265-270

Berlin A, Lalonde E, Sykes J, Zafarana G, Chu KC, Ramnarine VR, Ishkanian A, Sendorek DHS, Pasic I, Lam WL, Jurisica I, van der Kwast T, Milosevic M, Boutros PC, Bristow RG. NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer. *Oncotarget*. 2014 Nov; 5 (22) 11081-11090

Bhindi B, Kulkarni GS, Finelli A, Alibhai SMH, Hamilton RJ, Toi A, van der Kwast TH, Evans A, Hersey K, Jewett MAS, Zlotta AR, Trachtenberg J, Fleshner NE. Obesity is Associated with risk of progression for low-risk prostate cancers managed expectantly. *European Urology*. 2014 Nov; 66 (5) 841-848

Bhindi B, Margel D, Hamilton RJ, Fernandes KA, Trottier G, Hersey KM, Finelli A, Trachtenberg J, Zlotta A, Kulkarni GS, Toi A, Evans A, van der Kwast TH, Fleshner NE. The Impact of the use of Aspirin and other nonsteroidal anti-inflammatory drugs on the risk of prostate cancer detection on biopsy. *Urology*. 2014 Nov; 84 (5) 1073-1078

Bishop JL, Thaper D, Zoubeidi A. The Multifaceted Roles of STAT3 Signaling in the Progression of

Prostate Cancer. *Cancers*. 2014 Jun; 6 (2) 829-859

Bismar TA, Alshalalfa M, Petersen LF, Teng LH, Gerke T, Bakkar A, Al-Mami A, Liu SH, Dolph M, Mucci LA, Alhaji R. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. *BJU International*. 2014 Feb; 113 (2) 309-319

Boutros PC, Margolin AA, Stuart JM, Califano A, Stolovitzky G. Toward Better Benchmarking: Challenge-Based Methods Assessment in Cancer Genomics. *Genome Biology*. 2014 15 (9) 462

Bristow RG, Berlin A, Dal Pra A. An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. *British Journal of Radiology*. 2014 Mar; 87 20130753

Bujold KE, Fakhoury J, Edwardson TGW, Carneiro KMM, Briard JN, Godin AG, Amrein L, Hamblin GD, Panasci LC, Wiseman PW, Sleiman HF. Sequence-responsive unzipping DNA cubes with tunable cellular uptake profiles. *Chemical Science*. 2014 Mar; 5 (6) 2449-2455

Butz H, Szabo PM, Nofech-Mozes R, Rotondo F, Kovacs K, Mirham L, Girgis H, Boles D, Patocs A, Yousef GM. Integrative Bioinformatics Analysis Reveals New Prognostic Biomarkers of Clear Cell Renal Cell Carcinoma. *Clinical Chemistry*. 2014 Oct; 60 (10) 1314-1326

Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang YZ. GATA2 as a potential metastasis-driving gene in prostate cancer. *Oncotarget*. 2014 Jan; 5 (2) 451-461

Cho Choi-Fong, Shukla Sourabh, Simpson Emily J, Steinmetz Nicole F, Luyt Leonard G, Lewis John D. Molecular Targeted Viral Nanoparticles as Tools for Imaging Cancer. *Methods in Molecular Biology*. 2014 Aug; 1108 211-230

Choi SYC, Lin D, Gout PW, Collins CC, Xu Y, Wang YZ. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. *Advanced Drug Delivery Reviews*. 2014 Dec; 79-80 222-237

Chong LC, Albuquerque MA, Harding NJ, Caloian C, Chan-Seng-Yue M, de Borja R, Fraser M, Denroche RE, Beck TA, van der Kwast T, Bristow RG, McPherson JD, Boutros PC. SeqControl: process control for DNA sequencing. *Nature Methods*. 2014 Oct; 11 (10) 1071-1075

Couture F, Levesque C, Dumulon-Perreault V, Ait-Mohand S, D'Anjou F, Day R, Guerin B. PACE4-Based Molecular Targeting of Prostate Cancer Using an Engineered 64 Cu-Radiolabeled Peptide Inhibitor. *Neoplasia*. 2014 Aug; 16 (8) 634-643

Cramarossa G, Lee EK, Sivanathan L, Georgsdottir S, Lien K, Delos Santos K, Chan K, Emmenegger U. A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials. *Biomarkers in Medicine*. 2014 8 (6) 893-911

Crea F, Clermont PL, Mai A, Helgason CD. Histone Modifications, Stem Cells and Prostate Cancer. *Current Pharmaceutical Design*. 2014 Apr; 20 (11) 1687-1697

Dalal K, Roshan-Moniri M, Sharma A, Li HF, Ban FQ, Hessein M, Hsing M, Singh K, LeBlanc E, Dehm S, Guns EST, Cherkasov A, Rennie PS. Selectively Targeting the DNA Binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer. *Journal of Biological Chemistry*. 2014 Sep; 289 (38) 26417-26429

D'Anjou F, Couture F, Desjardins R, Day R. Knockdown strategies for the study of proprotein convertases and proliferation in prostate cancer cells. *Methods Mol Biol*. 2014; 1103 67-82

Di Sebastiano KM, Mourtzakis M. The Role of Dietary Fat throughout the Prostate Cancer Trajectory. *Nutrients*. 2014 Dec; 6 (12) 6095-6109

Dong, X. The androgen receptor is a key component of myometrium phenotype programming during pregnancy. *Receptors and Clinical Investigation*. 2014 Oct; 1 e326

Dryhurst D, Ausio J. Histone H2A.Z deregulation in prostate cancer. Cause or effect? . *Cancer and Metastasis Reviews*. 2014 Sep; 33 429-439

Edgcumbe Philip, Pratt Philip, Yang Guang-Zhong, Nguan Chris, Rohling Rob. Pico Lantern: A Pick-up Projector for Augmented Reality in Laparoscopic Surgery. *Lecture Notes in Computer Science*. 2014 Sep; 17 432-439

El Kaffas A, Nofiele J, Giles A, Cho S, Liu SK, Czarnota GJ. Dll4-Notch Signalling Blockade Synergizes Combined Ultrasound-Stimulated Microbubble and Radiation Therapy in Human Colon Cancer Xenografts. *PLoS One*. 2014 Apr; 9 (4) e93888

Forbrich Alex, Paproski Robert, Hitt Mary, Zemp Roger. Comparing Efficiency of micro-RNA and mRNA Biomarker Liberation with Microbubble-Enhanced Ultrasound Exposure. *Ultrasound in Medicine and Biology*. 2014 Sep; 40 (9) 2207-2216

Girgis H, Masui O, White NMA, Scorilas A, Rotondo F, Seivwright A, Gabril M, Filter ER, Girgis AHA, Bjarnason GA, Jewett MAS, Evans A, Al-Haddad S, Siu KWM, Yousef GM. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. *Molecular Cancer*. 2014 May; 13 101

Govind SK, Zia A, Hennings-Yeomans PH, Watson JD, Fraser M, Anghel C, Wyatt AW, van der Kwast T, Collins CC, McPherson JD, Bristow RG, Boutros PC. ShatterProof: operational detection and quantification of chromothripsis. *BMC Bioinformatics*. 2014 Mar; 15 78

Guillemette C, Levesque E, Rouleau M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. *Clinical Pharmacology and Therapeutics*. 2014 Sep; 96 (3) 324-339

Habeeb NMAWA, Ho LT, Olkhov-Mitsel E, Kron K, Pethe V, Lehman M, Jovanovic L, Fleshner N, van der Kwast T, Nelson CC, Bapat B. Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. *Oncotarget*. 2014 Sep; 5 (17) 7858-7869

Haerteis S, Krappitz A, Krappitz M, Murphy JE, Bertog M, Krueger B, Nacken R, Chung H, Hollenberg MD, Knecht W, Bunnett NW, Korbmacher C. Proteolytic activation of the human epithelial sodium channel by trypsin IV and trypsin I involves distinct cleavage sites. *Journal of Biological Chemistry*. 2014 July; 289 (27) 19067-19078

Hollenberg MD. KLKs and their hormone-like signaling actions: a new life for the PSA-KLK family. *Biological Chemistry*. 2014 Sep; 395 (9) 915-929

Huang KC, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA. The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy. *Cancer Biology and Therapy*. 2014 15 (9) 1120-1128

Huang KC, Dolph M, Donnelly B, Bismar TA. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer. *Clinical and Translational Oncology*. 2014 Nov; 16 (11) 973-979

Huang SP, Levesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdiere I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY. Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. *International Journal of Cancer*. 2014 Dec; 135 (11) 2661-2667

Huynh E, Zheng G. Porphysome nanotechnology: A paradigm shift in lipid-based supramolecular structures. *Nano Today*. 2014 Apr; 9 (2) 212-222

Jin Cheng S, Cui Liyang, Wang Fan, Chen Juan, Zheng Gang. Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. *Advanced Healthcare Materials*. 2014 Aug; 3 (8) 1240-1249-

KJH, Cox ME, Wasan KM. Effect of simvastatin on castration-resistant prostate cancer cells. *Lipids Health Dis.* 2014 Mar; 13 56

Klotz L, Emberton M. Management of low risk prostate cancer: active surveillance and focal therapy. *Current Opinion in Urology*. 2014 May; 24 (3) 270-279

Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. *Journal of Clinical Oncology*. 2014 Dec; 33 (3) 272-U75

Kolin David L, Sy Keiyan, Rotondo Fabio, Bassily Mena N, Kovacs Kalman, Brezden-Masley Christine, Streutker Catherine J, Yousef George M. Prognostic significance of human tissue kallikrein-related peptidases 11 and 15 in gastric cancer. *Tumor Biology*. 2014 Jan; 37 437-446

Kolin DL, Sy K, Rotondo F, Bassily MN, Kovacs K, Brezden-Masley C, Streutker CJ, Yousef GM. Prognostic significance of human tissue kallikrein-related peptidases 6 and 10 in gastric cancer. *Biological Chemistry*. 2014 Sep; 395 (9) 1087-1093

Kron KJ, Bailey SD, Lupien M. Enhancer alterations in cancer: a source for a cell identity crisis. *Genome Medicine*. 2014 Sep; 6 77

Kwiatkowska A, Couture F, Levesque C, Ly K, Desjardins R, Beauchemin S, Prah A, Lammek B, Neugebauer W, Dory YL, Day R. Design, Synthesis, and Structure–Activity Relationship Studies of a Potent PACE4 Inhibitor. *Journal of Medicinal Chemistry*. 2014 Jan; 57 (1) 98-109

Labbe DP, Nowak DG, Deblois G, Lessard L, Giguere V, Trotman LC, Tremblay ML. Prostate Cancer Genetic-susceptibility Locus on Chromosome 20q13 is Amplified and Coupled to Androgen Receptor-regulation in Metastatic Tumors. *Molecular Cancer Research*. 2014 Feb; 12 (2) 184-189

Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng XY, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie HL, Harding NJ, Mak DYF, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncology*. 2014 Dec; 15 (13) 1521-1532

Laverdiere I, Flageole C, Audet-Walsh E, Caron P, Fradet Y, Lacombe L, Levesque E, Guillemette C. The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. *Endocrine-Related Cancer*. 2014 Feb; 22 (1) 77-85

Leibowitz-Amit R, Seah JA, Atenafu EG, Templeton AJ, Vera-Badillo FE, Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. *European Journal of Cancer*. 2014 Sep; 50 (14) 2399-2407

Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, Hague MN, Ablack A, Carmine-Simmen K, McPherson VA, Postenka CO, Turley EA, Courtneidge SA, Chambers AF, Lewis JD. Invadopodia Are Required for Cancer Cell Extravasation and Are a Therapeutic Target for Metastasis. *Cell Reports*. 2014 Sep; 8 (5) 1558-1570

Levesque E, Laverdiere I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C. Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway. *Clinical Cancer Research*. 2014 Jun; 20 (11) 2971-2983

Levesque E, Laverdiere I, Lacombe L, Caron P, Rouleau M, Turcotte V, Tetu B, Fradet Y, Guillemette C. Importance of 5 α -reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.. *Clinical Cancer Research*. 2014 Feb; 20 (3) 576-584

Li H, Li Y, Morin D, Plymate S, Lye S, Dong X. The androgen receptor mediates antiapoptotic function in myometrial cells. *Cell Death and Disease*. 2014 July; 5 e1338

Li HF, Ban FQ, Dalal K, Leblanc E, Frewin K, Ma D, Adomat H, Rennie PS, Cherkasov A. Discovery of

Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor. *Journal of Medicinal Chemistry*. 2014 Aug; 57 (15) 6458-6467

Lin D, Wyatt AW, Xue H, Wang YW, Dong X, Haegert A, Wu R, Brahmabhatt S, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Coll A, Fazli L, Sharma M, Beltran H, Rubin M, Cox M, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang YZ. High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug Development. *Cancer Research*. 2014 Feb; 74 (4) 1272-1283

Liu LL, Dong XS. Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer Cells. *PLoS One*. 2014 Oct; 9 e108780

Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X. Mechanisms of the androgen receptor splicing in prostate cancer cells. *Oncogene*. 2014 Jun; 33 (24) 3140-3150

Longuespee R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, Gagnon S, Vergara D, Maffia M, Fournier I, Salzet M, Day R. Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. *Translational Oncology*. 2014 Jun; 7 (3) 410-419

Longuespee R, Tastet C, Desmons A, Kerdraon O, Day R, Fournier I, Salzet M. HFIP Extraction Followed by 2D CTAB/SDS-PAGE Separation: A New Methodology for Protein Identification from Tissue Sections after MALDI Mass Spectrometry Profiling for Personalized Medicine Research. *Omics - A Journal of Integrative Biology*. 2014 Jun; 18 (6) 374-384

Lotan TL, Carvalho FLF, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. *Modern Pathology*. 2014 Jan; 28 (1) 128-137

Lowes LE, Allan AL. Recent advances in the molecular characterization of circulating tumor cells. *Cancers*. 2014 Mar; 6 (1) 595-624

Lowes LE, Hedley BD, Keeney M, Allan AL. Adaptation of semi-automated circulating tumor cell (CTC) assays for clinical and preclinical research applications. *Journal of Visualized Experiments*. 2014 Feb; 84 e51248

Luk SUI, Xue H, Cheng HW, Lin D, Gout PW, Fazli L, Collins CC, Gleave ME, Wang YZ. The BIRC6 gene as a novel target of prostate cancer: dual targeting of inhibition of apoptosis. *Oncotarget*. 2014 Aug; 5 (16) 6896-6908

Mekhail Samy M, Yousef Peter G, Jackinsky Stephen W, Pasic Maria, Yousef George M. miRNA in prostate cancer - new prospects for old challenges. *Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine*. 2014 Apr; 25 (1) 79-98

Miller JK, Buchner N, Timms L, Tam S, Luo XM, Brown AMK, Pasternack D, Bristow RG, Fraser M,

Boutros PC, McPherson JD. Use of Sequenom sample ID Plus SNP genotyping in identification of FFPE tumor samples. *PLoS One*. 2014 Feb; 9 e88163

Mo F, Wyatt AW, Sun Y, Brahmabhatt S, McConeghy BJ, Wu CX, Wang YZ, Gleave ME, Volik SV, Collins CC. Systematic Identification and Characterization of RNA Editing in Prostate Tumors. *PLoS One*. 2014 July; 9 e101431

Moreel X, Allaire J, Leger C, Caron A, Labonte ME, Lamarche B, Julien P, Desmeules P, Tetu B, Fradet V. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. *Cancer Prevention Research*. 2014 July; 7 (7) 766-776

Munuganti RSN, Hassona MDH, Leblanc E, Frewin K, Singh K, Ma D, Ban FQ, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JPS, Zoubeidi A, Young RN, Guns ET, Rennie PS, Cherkasov A. Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. *Chemistry and Biology*. 2014 Nov; 21 (11) 1476-1485

Nawaz M, Camussi G, Valadi H, Nazarenko I, Ekstrom K, Wang XQ, Principe S, Shah N, Ashraf NM, Fatima F, Neder L, Kislinger T. The emerging role of extracellular vesicles as biomarkers for urogenital cancers. *Nature Reviews Urology*. 2014 Dec; 11 (12) 688-701

Ng KK, Shakiba M, Huynh E, Weersink RA, Roxin A, Wilson BC, Zheng G. Stimuli-Responsive Photoacoustic Nanoswitch for in Vivo Sensing Applications. *ACS Nano*. 2014 Aug; 8 (8) 8363-8373

Olkhov-Mitsel E, Zdravic D, Kron K, van der Kwast T, Fleshner N, Bapat B. Novel multiplex MethyLight Protocol for detection of DNA methylation in patient tissues and bodily fluids. *Scientific Reports*. 2014 Mar; 4 4432

Paproski RJ, Heinmiller A, Wachowicz K, Zemp RJ. Multi-wavelength photoacoustic imaging of inducible tyrosinase reporter gene expression in xenograft tumors. *Scientific Reports*. 2014 Jun; 4

Paproski Robert J, Forbrich Alexander, Hitt Mary, Zemp Roger. RNA biomarker release with ultrasound and phase-change nanodroplets. *Ultrasound in Medicine and Biology*. 2014 Aug; 40 (8) 1847-1856-

Park S, Ang RR, Duffy SP, Bazov J, Chi KN, Black PC, Ma HS. Morphological Differences Between Circulating Tumor Cells from Prostate Cancer Patients and Cultured Prostate Cancer Cells. *PLoS One*. 2014 Jan; 9 e85264

Real FX, Boutros PC, Malats N. Next-generation sequencing of urologic cancers: next is now. *European Urology*. 2014 July; 66 (1) 4-7

Roshan-Moniri M, Hsing M, Butler MS, Cherkasov A, Rennie PS. Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. *Cancer Treatment Reviews*. 2014 Dec; 40 (10) 1137-1152

Rotondo F, Di Ieva A, Kovacs K, Cusimano MD, Syro LV, Diamandis EP, Yousef GM. Human kallikrein 10

in surgically removed human pituitary adenomas. *Hormones*. 2014 Apr-Jun; 14 (2) 272-279

Samaan S, Lichner Z, Ding Q, Saleh C, Samuel J, Streutker C, Yousef GM. Kallikreins are involved in a miRNA network that contributes to prostate cancer progression. *Biological Chemistry*. 2014 Sep; 395 (9) 991-1001

Santa Mina D, Matthew AG, Hilton WJ, Au D, Awasthi R, Alibhai SMH, Clarke H, Ritvo P, Trachtenberg J, Fleshner NE, Finelli A, Wijeyesundera D, Aprikian A, Tanguay S, Carli F. Prehabilitation For Men Undergoing Radical Prostatectomy: A Multi-Centre, Pilot Randomized Controlled Trial. *BMC Surgery*. 2014 Nov; 14 89

Seo M, Matsuura N. Direct Incorporation of Lipophilic Nanoparticles into Monodisperse Perfluorocarbon Nanodroplets via Solvent Dissolution from Microfluidic-Generated Precursor Microdroplets. *Langmuir*. 2014 Oct; 30 (42) 12465-12473

Shao P, Harrison TJ, Zemp RJ. Consecutively reconstructing absorption and scattering distributions in turbid media with multiple-illumination photoacoustic tomography. *Journal. Of Biomedical Optics*. 2014 Dec; 19 UNSP 126009

Shaurya A, Dubicki KI, Hof F. Chemical agents for binding post-translationally methylated lysines and arginines. *Supramolecular Chemistry*. 2014 Jul-Aug; 26 583-590

Shi W, Paproski RJ, Moore R, Zemp R. Detection of circulating tumor cells using targeted surface-enhanced Raman scattering nanoparticles and magnetic enrichment. *Journal of Biomedical Optics*. 2014 May; 19 56014

Shulak L, Beljanski V, Chiang C, Dutta SM, Van Grevenynghe J, Belgnaoui SM, Nguyen TLA, Di Lenardo T, Semmes OJ, Lin RT, Hiscott J. Histone Deacetylase Inhibitors Potentiate Vesicular Stomatitis Virus Oncolysis in Prostate Cancer Cells by Modulating NF- κ B-Dependent Autophagy. *Journal of Virology*. 2014 Mar; 88 (5) 2927-2940

Simhadri C, Daze KD, Douglas SF, Quon TTH, Dev A, Gignac MC, Peng FN, Heller M, Boulanger MJ, Wulff JE, Hof F. Chromodomain antagonists that target the polycomb-group methyllysine reader protein Chromobox homolog 7 (CBX7) . *Journal of Medicinal Chemistry*. 2014 Apr; 57 (7) 2874-2883

Sivanathan L, Chow A, Wong A, Hoang VC, Emmenegger U. In vivo Passage of Human Prostate Cancer Cells in Mice Results in Stable Gene Expression Changes Affecting Numerous Cancer-Associated Biological Processes. *Prostate*. 2014 May; 74 (5) 537-546

Strohm EM, Gorelikov I, Matsuura N, Kolios MC. Modeling photoacoustic spectral features of micron-sized particles. *Physics in Medicine and Biology*. 2014 Oct; 59 (19) 5795-5810

Sun RX, Chong LC, Simmons TT, Houlihan KE, Prokopec SD, Watson JD, Moffat ID, Lensu S, Linden J, P'ng C, Okey AB, Pohjanvirta R, Boutros PC. Cross-species transcriptomic analysis elucidates constitutive aryl hydrocarbon receptor activity. *BMC Genomics*. 2014 Dec; 15 1053

Toren P, KS, Cordonnier T, Crafter C, Davies BR, Fazli L, Gleave ME, Zoubeidi A. Combination AZD5363 with enzalutamide significantly delays enzalutamide resistant prostate cancer through induction of apoptosis and cell cycle arrest. *European Urology*. 2014 Jun; 67 (6) 986-990

Toren PJ, KS, Pham S, Mangalji A, Adomat H, Guns EST, Zoubeidi A, Moore W, Gleave ME. Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer. *Molecular Cancer Therapeutics*. 2014 Jan; 14 (1) 59-69

Usmani N, Leong N, Martell K, Lan L, Ghosh S, Pervez N, Pedersen J, Yee D, Murtha A, Amanie J, Sloboda R, Murray D, Parliament M. Single-nucleotide polymorphisms studied for associations with urinary toxicity from (125)I prostate brachytherapy implants. *Brachytherapy*. 2014 May-June; 13 285-291

White NMA, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, Siu KWM, Yousef GM. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. *British Journal of Cancer*. 2014 Mar; 110 (5) 1250-1259

White NMA, Newsted DW, Masui O, Romaschin AD, Siu KWM, Yousef GM. Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma. *Tumor Biology*. 2014 Mar; 35 (3) 1833-1846

Williams JL, Greer PA, Squire JA. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. *Cancer Genetics*. 2014 Oct-Dec; 207 (43079) 474-488

Wong N, Yan J, Ojo D, De Melo J, Cutz JC, Tang D. Changes in PKM2 associate with prostate cancer progression. *Cancer Investigation*. 2014 Aug; 32 (7) 330-338

Wyatt AW, Mo F, Wang K, McConeghy B, Brahmabhatt S, Jong LN, Mitchell DM, Johnston RL, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk AV, McPherson A, Shukin R, Bell RH, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan AM, Mehra R, Lin D, Wang YZ, Fazli L, Gleave ME, Volik SV, Collins CC. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. *Genome Biology*. 2014 15 (8) 426

Xie N, Cheng HL, Lin D, Liu LL, Yang O, Jia L, Fazli L, Gleave ME, Wang YZ, Rennie P, Dong XS. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. *International Journal of Cancer*. 2014 Feb; 136 (4) E27-E38

Xu B, Teng LH, da Silva SD, Bijian K, Al Bashir S, Jie S, Dolph M, Alaoui-Jamali MA, Bismar TA. The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. *Cancer Medicine*. 2014 Feb; 3 (1) 14-24

Yan J, De Melo J, Cutz JC, Aziz T, Tang D. Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis. *British Journal of Cancer*. 2014 May; 110 (10) 2593-2603

Yohan D, KA, Korpela E, Liu S, Niu C, Wilson BC, Chin LCL. Quantitative monitoring of radiation induced skin toxicities in nude mice using optical biomarkers measured from diffuse optical reflectance spectroscopy. *Biomedical Optics Express*. 2014 May; 5 (5) 1309-1320

Yu Y, Lee JS, Xie N, Li E, Hurtado-Coll A, Fazli L, Cox M, Plymate S, Gleave M, Dong XS. Prostate stromal cells express the progesterone receptor to control cancer cell mobility. *PLoS One*. 2014 Mar; 9 e92714

Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylnina M, Aldaoud N, Fleshner N, Finelli A, Klotz L, Lockwood G, Sykes J, van der Kwast T. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in asian and caucasian men. *European Urology*. 2014 Oct; 66 (4) 619-622